Showing 2031-2040 of 5696 results for "".
- Doctor Alexa Will See You Now: Is Amazon Primed To Come To Your Rescue?https://modernod.com/news/doctor-alexa-will-see-you-now-is-amazon-primed-to-come-to-your-rescue/2476782/Now that it’s upending the way you play music, cook, shop, hear the news and check the weather, the friendly voice emanating from your Amazon Alexa-enabled smart speaker is poised to wriggle its way into all things health care. Amazon has big ambitions for its devices, according to a
- Now Optics Launches New Advertising Campaign ‘The Perfect Fit’https://modernod.com/news/now-optics-launches-new-advertising-campaign-the-perfect-fit/2476780/Now Optics, which provides eyewear under the retail brands Stanton Optical and My Eyelab, has announced a new advertising campaign, ‘The Perfect Fit.’ Developed in conjunction with its agency, Barkley, ‘The Perfect Fit’ highlights walk-in eye exam appointments, eyeglasses and eyewear assor
- Notal Vision Diagnostic Clinic Reports Completion of 6 Million ForeseeHome AMD Home-Monitoring Testshttps://modernod.com/news/notal-vision-diagnostic-clinic-reports-completion-of-6-million-foreseehome-amd-home-monitoring-tests/2476750/Notal Vision announced the completion of 6 million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD, according to a company news release. ForeseeHo
- SIFI Announces Expansion in the French Market With Acquisition of Dacudoses and Novoptinehttps://modernod.com/news/sifi-announces-expansion-in-the-french-market-with-acquisition-of-dacudoses-and-novoptine/2479574/Italian ophthalmic company SIFI has announced the acquisition of Dacudoses and Novoptine antiseptic brands in France from Laboratoire Gifrer Barbezat. Terms of the deal were not disclosed. Dacudoses is the leading reimbursed RX brand of the French ophthalmic antiseptic segment, pres
- Hoya Surgical Optics Obtains CE Mark for Nanex multiSert+ IOL Delivery Systemhttps://modernod.com/news/hoya-surgical-optics-obtained-ce-mark-for-nanex-multisert-iol-delivery-system/2476708/Hoya Surgical Optics has obtained CE Mark for Nanex multiSert+, which consists of a a new IOL delivered in a first-of-its kind preloaded delivery system, according to a company news release. The 1.62 mm injector tip of multiSert+ is the world’s smallest nozzle size in
- Ocular Therapeutix Receives FDA Approval of Supplemental NDA for Dextenza for Postoperative Ocular Inflammationhttps://modernod.com/news/ocular-therapeutix-receives-fda-approval-of-supplemental-nda-for-dextenza-for-the-treatment-of-ocular-inflammation-following-ophthalmic-surgery/2476680/Ocular Therapeutix announced the FDA approved a supplemental new drug application (NDA) for Dextenza to include the treatment of ocular inflammation following ophthalmic surgery as an additional indication. With the approval of the supplemental NDA, Dextenza is now approved for the treatment of b
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- First Patient Dosed in Phase 2 Trial Evaluating Ocular Delivery of ST266 For the Treatment of Persistent Corneal Epithelial Defectshttps://modernod.com/news/noveome-biotherapeutics-announces-the-first-patient-dosed-in-phase-2-open-label-clinical-trial-evaluating-topical-ocular-delivery-of-st266-for-the-treatment-of-persistent-corneal-epithelial-defects/2476652/Noveome Biotherapeutics announced the dosing of the first patient in its phase 2 open label, multicenter clinical trial evaluating topical ocular delivery of ST266 for the treatment of persistent corneal epithelial defects (PEDs), for which there are limited treatment options. “The dosing
- Roche’s Purchase of Spark Therapeutics Faces Further Delay Amid Scrutiny From US, UK Regulatorshttps://modernod.com/news/roches-purchase-of-spark-therapeutics-faces-further-delay-amid-scrutiny-from-us-uk-regulators/2476640/The US Federal Trade Commission requested additional information and documentary material from Roche and Spark Therapeutics in connection with its review of the companies’ pending deal, the drugmakers reported Monday. Roche noted that as a result, its $4.3-billion offer to acquire Spark has
- Evaluation of a Remote Diagnosis Imaging Model vs Dilated Eye Examination in Referable Macular Degenerationhttps://modernod.com/news/evaluation-of-a-remote-diagnosis-imaging-model-vs-dilated-eye-examination-in-referable-macular-degeneration/2476596/Researchers examined if the identification of referable macular degeneration could be done using the remote diagnosis imaging model as a clinical screening tool. They conducted a nonrandomized study of 159 patients in facilities with high rates of diabetic retinopathy and age-related macular dege